Archrivals face battle with a new enemy

Pfizer and MSD - long-time rivals in the competitive vaccine space for pneumococcal disease - may have a new enemy, with Vaxcyte's VAX-31 matching both company's pneumococcal conjugate vaccines (PCVs) in a phase 3 trial, with plans for a market launch in 2028.

To see the whole article please log in.

Simon Webster

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here